Overview: Alpha-1-Antitrypsin Quantitative TestIntroduction: The Alpha-1-Antitrypsin Quantitative Test measures AAT levels to diagnose deficiency, which may cause lung or liver problems like shortness of breath or jaundice. Aligned with 2023 ATS guidelines, it uses spectrophotometry for high accuracy, aiding in metabolic screening. This test is critical for guiding treatment, monitoring disease progression, and improving outcomes in biochemistry, particularly for patients with respiratory or hepatic symptoms.
Other Names: AAT Quantitative Assay, Alpha-1-Antitrypsin Level Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: AAT deficiency was identified in the 1960s. Quantitative assays emerged in the 1970s, and by the 2000s, spectrophotometric methods improved precision for AAT measurement.
Purpose: Diagnoses AAT deficiency, guides treatment, and monitors disease risk in patients with symptoms like shortness of breath or jaundice.
Test Parameters: 1. Alpha-1-Antitrypsin
Pretest Condition: Fasting for 10-12 hours required to stabilize protein levels. Collect serum or plasma after overnight fasting. Report symptoms like shortness of breath or jaundice, and list medications like augmentation therapy.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document respiratory or liver symptoms, smoking history, or family history of AAT deficiency. Include current medications, especially augmentation therapy.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for further testing or treatment.
Procedural Considerations: Uses spectrophotometry to measure AAT levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or inflammation may elevate AAT levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Low AAT levels confirm deficiency, prompting augmentation therapy or lifestyle changes. Normal levels may require phenotyping to identify genetic variants.
Specialist Consultation: Consult a pulmonologist or hepatologist for result interpretation. Genetic counseling is advised for confirmed deficiency.
Additional Supporting Tests: AAT phenotype test, liver function tests, or pulmonary function tests to confirm deficiency or assess organ damage.
Test Limitations: Inflammation or acute-phase reactions may mask deficiency. Genetic phenotyping is needed to confirm specific variants.
References: ATS/ERS AAT Deficiency Guidelines, 2023; American Journal of Respiratory and Critical Care Medicine, Sandhaus RA, 2022.
